A Double-Blind, Placebo-Controlled Efficacy (as Assessed by Post-Bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-Related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2016
At a glance
- Drugs Palovarotene (Primary)
- Indications Emphysema
- Focus Therapeutic Use
- Acronyms TESRA
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 30 Jun 2011 New source identified and integrated (European Clinical Trials Database).
- 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.